327 related articles for article (PubMed ID: 9843170)
1. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
[TBL] [Abstract][Full Text] [Related]
2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
3. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
5. Management of hemophilia patients with inhibitors.
Hedner U; Glazer S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
[TBL] [Abstract][Full Text] [Related]
6. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
[TBL] [Abstract][Full Text] [Related]
7. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
8. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
[TBL] [Abstract][Full Text] [Related]
9. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
10. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
[TBL] [Abstract][Full Text] [Related]
11. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
[TBL] [Abstract][Full Text] [Related]
12. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
13. The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies.
Simic D; Milojevic I
Paediatr Anaesth; 2007 Aug; 17(8):789-92. PubMed ID: 17596224
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
Petrini P; Klementz G
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
[TBL] [Abstract][Full Text] [Related]
15. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
[TBL] [Abstract][Full Text] [Related]
16. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
18. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
[TBL] [Abstract][Full Text] [Related]
19. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]